Clinical trials: Headache Disorders, Primary
Migraine
A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
Researchers are trying to learn whether a drug called Lu AG09222 can help prevent migraine headaches for people who have not been helped by other treatments that are used to prevent migraines.
- Trial name
- NCT05133323
- Testing
- Lu AG09222
- Where
- 28 sites in United States, Czechia and 4 more
- Volunteers
- 237 people
- Sponsor
- H. Lundbeck A/S
Cluster Headache
An Open Label Study Using Consecutive Intravenous Depacon With Oral Depakote ER for the Treatment of Cluster Headaches.
The purpose of this study is to collect and evaluate information on the use of Depakote Extended Release (ER) and Depacon Intravenous (IV) in patients with cluster headaches.
- Trial name
- NCT00203242
- Testing
- Depacon IV and Depakote ER
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Thomas Jefferson University
Cyclic Vomiting Syndrome, Abdominal Migraine
Auricular Neurostimulation for Cyclic Vomiting Syndrome
This study evaluates the efficacy of auricular neurostimulation via an non-invasive percutaneous electrical nerve field stimulator in children and adults with cyclic vomiting syndrome.
- Trial name
- NCT03434652
- Testing
- Percutaneous neurostimulation
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Medical College of Wisconsin
Cluster Headache
Non-invasive Neurostimulation of the Vagus Nerve for the Treatment of Cluster Headache
Multi-center, prospective, double-blind, randomized, sham-controlled pivotal study of non-invasive vagus nerve stimulation with the GammaCore® device for the acute treatment of cluster headache.
- Trial name
- CH (NCT01792817)
- Testing
- GammaCore
- Where
- 20 sites in United States
- Volunteers
- 150 people
- Sponsor
- ElectroCore INC
Migraine Disorders
Biomarker Study in Participants With Migraine
This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo.
- Trial name
- NCT02766517
- Testing
- Capsaicin
- Where
- 14 sites in United States
- Volunteers
- 37 people
- Sponsor
- Eli Lilly and Company
Hypertension, Heart Failure
LSFG-SKIN, Laser Speckle Flowgraphy
The purpose of this project is to quantify normal and abnormal skin blood flow regionally in different areas of the body(face, extremities, over burns and wounds) at baseline and over time in response to treatment or…
- Conditions
- Hypertension, Heart Failure, Vascular Ischemia, Burns
- Trial name
- NCT03660618
- Testing
- laser speckle flowgraphy
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Randy Kardon
Tension-Type Headache
Safety and Efficacy Study of TNX-201 Capsules for Treatment of Single Tension-Type Headache
This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of a single dose of TNX-201 (140 mg) for the treatment of a single qualifying Tension-Type-Headache…
- Trial name
- NCT02423408
- Testing
- TNX-201
- Where
- 10 sites in United States
- Volunteers
- 165 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Episodic Migraine
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018).
- Trial name
- NCT05028569
- Testing
- BOTOX
- Where
- 133 sites in United States, Canada and 7 more
- Volunteers
- 775 people
- Sponsor
- AbbVie
Pain, Migraine
Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine
The main purpose of this study is to compare the efficacy and safety of aspirin, acetaminophen and caffeine (AAC) with sumatriptan and placebo in the acute treatment of migraine.
- Trial name
- NCT01248468
- Testing
- Aspirin, acetaminophen and caffeine, Sumatriptan
- Where
- 20 sites in United States
- Volunteers
- 752 people
- Sponsor
- Novartis
Migraine
A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study followed by an open-label treatment phase (OLTP).
- Trial name
- NCT02630459
- Testing
- Erenumab
- Where
- 44 sites in Japan
- Volunteers
- 475 people
- Sponsor
- Amgen
Migraine
A Dose-Finding Study of MK0974 in Acute Migraine (MK0974-004)
The purpose of this study is to investigate the efficacy and safety of an MK 0974 for migraine headache and to identify an appropriate dose range for further study.
- Trial name
- NCT00246337
- Testing
- MK0974, Rizatriptan
- Volunteers
- 420 people
- Sponsor
- Merck Sharp & Dohme LLC
Migraine
A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments
Evaluation of eptinezumab in the prevention of migraine in participants with unsuccessful prior preventive treatments.
- Trial name
- DELIVER (NCT04418765)
- Testing
- Eptinezumab
- Where
- 138 sites in United States, Belgium and 15 more
- Volunteers
- 892 people
- Sponsor
- H. Lundbeck A/S
Intervention
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.
- Trial name
- NCT02991430
- Testing
- active neuromodulation for episodic migraine headache
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- Scion NeuroStim
Migraine
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine
The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.
- Trial name
- CONQUER (NCT03559257)
- Testing
- Galcanezumab
- Where
- 69 sites in United States, Belgium and 11 more
- Volunteers
- 463 people
- Sponsor
- Eli Lilly and Company
Migraine Disorders
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute…
- Trial name
- Adelphi DSP (NCT06412965)
- Where
- United States
- Volunteers
- 528 people
- Sponsor
- Pfizer
Migraine
MLD10 in the Prevention of Migraine in Adults
This is a double-blind, placebo-controlled, randomized, multi-center study. Subjects agreeing to participate in the study and meet the entry criteria assessed at the screening visit, will begin a 28 day baseline period to confirm…
- Trial name
- NCT02322333
- Testing
- MLD10
- Where
- 9 sites in United States
- Volunteers
- 157 people
- Sponsor
- Pharmalyte Solutions LLC
Migraine
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
The purpose of this study is to learn about the effects of Rimegepant to help prevent migraine. This study is seeking for participants who: Are male and female of 18 years of age or older.
- Trial name
- NCT05810038
- Testing
- Rimegepant
- Where
- 49 sites in China
- Volunteers
- 787 people
- Sponsor
- Pfizer
Migraine
A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting
We are testing the hypothesis that subjects in the treatment group will experience fewer fasting induced headaches as compared to those in the placebo group.In our clinical experience, we estimate that approximately 25% of our…
- Trial name
- NCT00440232
- Testing
- Frovatriptan
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Thomas Jefferson University
Migraine With Aura
Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura
Assess safety and efficacy of Transcranial Magnetic Stimulation (TMS) for the treatment of migraine with aura The hypothesis is that TMS treatments delivered to the occipital cortex of the brain can stop or interrupt the…
- Trial name
- NCT00449540
- Testing
- Active Transcranial Magnetic Stimulation (TMS) Device
- Where
- 14 sites in United States
- Volunteers
- 201 people
- Sponsor
- Neuralieve
Migraine
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
This study will evaluate the potential for a pharmacokinetic (PK) interaction and provide safety and tolerability information when ubrogepant and erenumab or ubrogepant and galcanezumab are co-administered.
- Trial name
- NCT04179474
- Testing
- Ubrogepant, Erenumab, Galcanezumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Allergan